Johnson & Johnson (J&J) has temporarily paused production of its Covid-19 vaccine to pursue something more lucrative, but SA will not fall victim to the shortfall.

The pause in production, according to the New York Times, is a worry for much of the developing world as the J&J vaccine is their main supply in the fight against Covid-19...

Subscribe now to unlock this article.

Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).

There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.

Cancel anytime.